Endpoints News· Ryan Cross·· 59 分钟前AI 评分62
FDA 为个体化基因编辑疗法明确审批路径
FDA charts path for approval of individualized gene editing therapies
AI 导读
FDA 概述了药企为针对单个人致病突变定制的基因编辑药物申请监管批准可采取的步骤。Endpoints News 报道了这一监管路径，但文章正文需注册后才能阅读。
正文 · 原文
The FDA has outlined steps drugmakers can take to seek regulatory approval for gene editing medicines tailored to fix a single person’s disease-causing mutation.
The …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源：Endpoints News · endpoints.news